UNION CITY, Calif., April 30, 2015 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fourth quarter and fiscal year ended March 31, 2015.
Fourth quarter and fiscal 2015 overview:
- Revenues from continuing operations of $52.0 million for the fourth quarter, up 33% over last year’s comparable quarter, and $202.6 million for fiscal 2015, up 25% year-over-year.
- Diluted EPS of $0.50 for the fourth quarter, up 194% over last year’s comparable quarter, and $1.20 for fiscal 2015, up 90% year-over-year. Diluted EPS for the fourth quarter and full fiscal year ended March 31, 2015 includes the effect of the gain on sale of Abaxis’ AVRL business unit, as further described in “Discontinued Operations” below.
Revenues highlights:
- North America revenues from continuing operations for the fourth quarter of $41.8 million, up 39% over last year’s comparable quarter, and $163.3 million for fiscal 2015, up 29% year-over-year.
- International revenues for the fourth quarter of $10.2 million, up 11% over last year’s comparable quarter, and $39.3 million for fiscal 2015, up 11% year-over-year.
- Medical market revenues for the fourth quarter of $8.7 million, up 22% over last year’s comparable quarter, and $35.4 million for fiscal 2015, up 26% year-over-year.
- Veterinary market revenues for the fourth quarter of $42.6 million, up 36% over last year’s comparable quarter, and $164.0 million for fiscal 2015, up 25% year-over-year.
- Total medical and veterinary instrument revenues for the fourth quarter of $11.7 million, up 63% over last year’s comparable quarter, and $48.6 million for fiscal 2015, up 30% year-over-year.
- Total medical and veterinary instrument sales of 1,536 units for the fourth quarter, up 45% over last year’s comparable quarter, and 6,791 units for fiscal 2015, up 28% year-over-year.
- Total medical and veterinary reagent disc revenues for the fourth quarter of $29.3 million, up 24% over last year’s comparable quarter, and $111.1 million for fiscal 2015, up 24% year-over-year.
- Total medical and veterinary reagent disc sales of 2.3 million units for the fourth quarter, up 23% over last year’s comparable quarter, and 8.5 million units for fiscal 2015, up 22% year-over-year.
Other financial highlights:
- Gross profit from continuing operations of $28.4 million for the fourth quarter, up 35% over last year’s comparable quarter, and $109.0 million for fiscal 2015, up 30% year-over-year.
- Cash, cash equivalents and investments as of March 31, 2015 of $157.3 million, an increase of $36.1 million from March 31, 2014.
- Abaxis paid dividends of $9.0 million in fiscal 2015.
Clint Severson, chairman and chief executive officer of Abaxis, added, “The fourth quarter was strong and continued the trend of the previous three quarters of the year, making fiscal 2015 an excellent year for Abaxis. We generated strong revenue growth, culminating in record revenues from continuing operations for the fiscal year of $202.6 million. In our veterinary market segment, the growth was driven in North America as revenues from sales of our VetScan VS2 instruments and consumables increased by 56% and 32%, respectively, year-over-year. In our medical market segment, revenues from sales of Piccolo products continued to gain traction with strong double-digit growth in the fourth quarter and the fiscal year. Although in the European market, unit sales of our Piccolo and VetScan VS2 products increased, we faced challenges from global economic uncertainties, especially from the effect of a strong U.S. dollar on the remeasurement of foreign-denominated sales into dollars as we recorded a loss on foreign currency of $1.8 million during fiscal 2015.”
“The operational and financial results generated this year are a testament to the focus and dedication of the entire Abaxis team,” continued Mr. Severson. “We have initiated a number of strategic changes over the past few years to make Abaxis more efficient and more responsive to our markets. Our employees have stepped up to the challenge and the results are beginning to reflect those efforts. As a result, we successfully obtained regulatory clearance on a number of rapid tests and expanded our national distribution network in the veterinary market. Additionally, our distribution partners have also responded positively by penetrating the market to a greater extent as they have become increasingly more aware of the features and benefits of our diagnostic products.”
“In fiscal 2015, we invested in research and development to develop new products to lead us into the future. At the end of fiscal 2015, we continue to maintain a strong financial base with cash, cash equivalents and investments of $157.3 million. As we move into fiscal 2016, we believe we are well positioned to continue to build on this positive trend and leverage our strategic partnerships to drive growth and market share. “
Dividend Declared
Abaxis today announced that its Board of Directors declared an increase in the quarterly dividend from $0.10 to $0.11 per common share, to be paid on June 18, 2015, to all shareholders of record as of the close of business on June 4, 2015. This represents a 10% increase compared to the prior quarterly dividend.
Results of Continuing Operations
Quarterly Results
For the fiscal quarter ended March 31, 2015, Abaxis reported revenues from continuing operations of $52.0 million, as compared with revenues of $39.2 million for the comparable period last year, an increase of 33 percent. Revenues from sales of instruments, which include chemistry analyzers, hematology instruments, VSpro specialty analyzers and iSTAT analyzers, increased by $4.5 million, or 63 percent, compared to the same period last year. Revenues from sales of consumables, which include reagent discs, hematology reagent kits, VSpro specialty cartridges, iSTAT cartridges and rapid tests, increased by $7.7 million, or 25 percent, compared to the same period last year. Abaxis reported net income from continuing operations of $3.8 million for the fiscal quarter ended March 31, 2015, compared to $4.1 million for the fiscal quarter ended March 31, 2014. Abaxis’ effective tax rate in the quarter ended March 31, 2015 was 42 percent, compared to 36 percent for the same period last year. The effective tax rate for the fourth quarter of fiscal 2015 was negatively impacted in part from non-recurring non-deductible expenses incurred during the period. Abaxis reported diluted net income per share from continuing operations of $0.17 (calculated based on 22,870,000 shares) for the three-month period ended March 31, 2015, compared to $0.19 per share (calculated based on 22,547,000 shares) for the same period last year.
Fiscal 2015 Results
For the fiscal year ended March 31, 2015, Abaxis reported revenues from continuing operations of $202.6 million, as compared with revenues of $162.0 million for the prior year, an increase of 25 percent. Revenues from instrument sales increased by $11.1 million, or 30 percent, over the prior year. Revenues from sales of consumables increased by $26.9 million, or 23 percent, over the prior year. The company reported net income from continuing operations of $20.8 million for fiscal 2015, compared to $16.2 million for the prior year. The company’s effective tax rate in fiscal 2015 was 37 percent, compared to 36 percent for the prior year. The company reported diluted net income per share from continuing operations of $0.91 (calculated based on 22,787,000 shares) for fiscal 2015, compared to $0.72 per share (calculated based on 22,575,000 shares) for fiscal 2014.
Other Reported Information
Non-cash compensation expense recognized for share-based awards during the fourth quarter of fiscal 2015 was $2.6 million, compared to $1.9 million for the same period last year. Abaxis paid $2.3 million in cash dividends to shareholders during the fourth quarter of fiscal 2015.
Discontinued Operations
On March 18, 2015, we entered into an Asset Purchase Agreement with Antech Diagnostics, Inc. pursuant to which we sold substantially all of the assets of our Abaxis Veterinary Reference Laboratories (“AVRL”) business. The transaction closed on March 31, 2015. The total purchase price under the Agreement is $21.0 million in cash. We received $20.1 million in cash proceeds during the fourth quarter of fiscal 2015, while the remaining $0.9 million is being held in escrow until certain conditions are met, upon which proceeds may be released on the one year anniversary of the closing.
The sale of our AVRL business unit, which was previously reported within our veterinary market segment, resulted in a pre-tax gain of $12.3 million ($7.7 million after-tax) for the fiscal year ended March 31, 2015. The pre-tax gain on this sale reflects the excess of the sum of the cash proceeds received over the costs incurred in connection with the sale of AVRL. During the fourth quarter of fiscal 2015, we recorded costs of $7.8 million related to cash payments for employee-related costs, including costs for severance, contract termination and other associated costs, and a non-cash charge for the impairment of fixed assets and other assets. These costs partially offsets the cash proceeds that the Company received in accordance with the terms of the Agreement.
Conference Call
Abaxis has scheduled a conference call to discuss its financial results at 4:15 p.m. Eastern Time on Thursday, April 30, 2015. Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet webcast, which is available in the Investor Relations section of the company’s website at http://www.abaxis.com. A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10064238, through May 6, 2015. This press release is also available prior to and after the call via Abaxis’ website or the Securities and Exchange Commission’s website at http://www.sec.gov.
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visit http://www.abaxis.com.
Forward Looking Statements
This press release includes, and our conference call will include, statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Abaxis’ cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis’ conference call may be affected by risks and uncertainties, including, but not limited to, those related to risks related to the transition of its U.S. medical sales to Abbott, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Abaxis’ facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis’ products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis’ intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
